First-trimester use seems safe, although data are still limited.
As many as 8 in 10 women experience debilitating pregnancy-associated nausea and vomiting. Ondansetron, which has emerged as the most common therapy for chemotherapy-associated nausea and vomiting, also appears to be the most effective drug during pregnancy — but is it safe? In a systematic review and a separate in-depth commentary based on a literature search, two groups address this question.
In the systematic review of potential malformations following first-trimester exposure to ondansetron, researchers identified some 4000 exposed infants in eight studies. Overall, no excess risk for major malformations was seen, although risk for septal heart defects was slightly increased in two studies; in addition, risk for cleft palate was increase…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)